These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 11836634

  • 1. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M.
    Anticancer Res; 2002 Mar; 22(2A):831-6. PubMed ID: 12014659
    [Abstract] [Full Text] [Related]

  • 3. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [Abstract] [Full Text] [Related]

  • 4. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A, Tada Y, Kawamura K, Takiguchi Y, Tatsumi K, Kuriyama T, Takenouchi T, O-Wang J, Tagawa M.
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [Abstract] [Full Text] [Related]

  • 5. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
    Tada Y, O-Wang J, Yu L, Shimozato O, Wang YQ, Takiguchi Y, Tatsumi K, Kuriyama T, Takenaga K, Sakiyama S, Tagawa M.
    Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
    [Abstract] [Full Text] [Related]

  • 6. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A.
    J Immunol; 1999 Jun 15; 162(12):7350-7. PubMed ID: 10358186
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.
    Immunol Lett; 2004 Feb 15; 91(2-3):119-26. PubMed ID: 15019279
    [Abstract] [Full Text] [Related]

  • 9. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.
    Int Immunopharmacol; 2005 Feb 15; 5(2):281-8. PubMed ID: 15652759
    [Abstract] [Full Text] [Related]

  • 10. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D, Benihoud K, Kiger N, Bobé P.
    J Leukoc Biol; 2005 Nov 15; 78(5):1052-9. PubMed ID: 16204618
    [Abstract] [Full Text] [Related]

  • 11. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
    Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.
    Cancer Gene Ther; 2004 Mar 15; 11(3):237-48. PubMed ID: 14739939
    [Abstract] [Full Text] [Related]

  • 12. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF, Sun J, Lang J, Vacano G, Patterson D, Chan D, Franzusoff A, Gianani R, Meech SJ, Duke R, Bellgrau D.
    Clin Immunol; 2004 Jul 15; 112(1):54-65. PubMed ID: 15207782
    [Abstract] [Full Text] [Related]

  • 13. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 14. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects.
    Wang YQ, Wada A, Ugai S, Tagawa M.
    Oncol Rep; 2003 Nov 01; 10(4):909-13. PubMed ID: 12792744
    [Abstract] [Full Text] [Related]

  • 15. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M, Fontana A, Takeda Y, Yoshimoto T, Tsubura A, Matsuzawa A.
    Cell Immunol; 2001 Jan 10; 207(1):41-8. PubMed ID: 11161452
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A.
    Eur J Immunol; 1995 Aug 10; 25(8):2253-8. PubMed ID: 7545115
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS, Koh S, Huang E, Saff RR, Marshak-Rothstein A, Mukai S, Ksander BR.
    Invest Ophthalmol Vis Sci; 2005 Jul 10; 46(7):2495-502. PubMed ID: 15980241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.